QRVO
81
7
STI
69
-9
MPC
52
10
UA
33
3
TRIP
75
9
PNW
45
-4
SO
59
-3
CMS
54
-6
NOC
47
-6
DFS
64
2
IP
33
3
FSLR
60
5
NTAP
65
4
ROK
46
3
LLY
56
2
GS
78
2
CAG
47
3
MSI
55
-3
UNM
68
-2
AVGO
52
8
QRVO
81
7
STI
69
-9
MPC
52
10
UA
33
3
TRIP
75
9
PNW
45
-4
SO
59
-3
CMS
54
-6
NOC
47
-6
DFS
64
2
IP
33
3
FSLR
60
5
NTAP
65
4
ROK
46
3
LLY
56
2
GS
78
2
CAG
47
3
MSI
55
-3
UNM
68
-2
AVGO
52
8
Financhill
Back

Theravance Biopharma 10K Form

Sell
47

TBPH
Theravance Biopharma

Last Price:
9.11
Seasonality Move:
-13.46%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive TBPH News And Ratings

See the #1 stock for the next 7 days that we like better than TBPH

TBPH Financial Statistics

Sales & Book Value

Annual Sales: $57.42M
Cash Flow: $-1.53M
Price / Cash Flow: 0
Annual Sales: $4.43
Price / Book: 2.06

Profitability

EPS (TTM): -0.97000
Net Income (TTM): $-55.19M
Gross Margin: $71.86M
Return on Equity: -17.79%
Return on Assets: -11.56%

Theravance Biopharma Earnings Forecast

Key Theravance Biopharma Financial Ratios

  • The Gross Profit Margin over the past 9 years for TBPH is 100.00%.
  • The Selling, General & Administrative Expenses for TBPH have been equal to 122.69% of Gross Profit Margin.
  • The Research & Development expenses have been 70.74% of Revenue.
  • The Interest Expense is -4.26% of Operating Income.
  • The Net Earning history of TBPH is -96.11% of Total Revenues.
  • Per Share Earnings over the last 12 years have been positive in 5 years.

Theravance Biopharma Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: TBPH
CUSIP: G8807B
Website: theravance.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 5.39
Quick Ratio: 4.84

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 26.43

TBPH Technical Analysis vs Fundamental Analysis

Sell
47
Theravance Biopharma (TBPH) is a Sell

Is Theravance Biopharma a Buy or a Sell?